Transthyretin amyloid cardiomyopathy (ATTR-CM) is a progressive condition that can be caused by genetic mutations or aging, and is characterized by accumulating heart damage that ultimately leads to symptoms of heart failure. In ATTR-CM,…
The most common signs of transthyretin amyloid cardiomyopathy (ATTR-CM) are those typically associated with heart failure, although problems in the nervous system or other tissues can also occur. ATTR-CM is a type of cardiac amyloidosis,…
A diagnosis of transthyretin amyloid cardiomyopathy (ATTR-CM) is typically reached through a series of tests to identify signs of the disease and rule out related disorders. ATTR-CM is a type of heart amyloidosis, a group…
The treatment of transthyretin amyloid cardiomyopathy (ATTR-CM) is a multidisciplinary effort involving interventions to slow disease progression and manage symptoms. ATTR-CM is a form of amyloidosis, where protein clumps, called amyloid deposits, accumulate in tissues.
Transthyretin amyloid cardiomyopathy (ATTR-CM) is a form of heart disease that’s typically caused by genetic mutations or aging. Determining the root cause of ATTR-CM can help guide treatment decisions, understand prognosis, and determine if family…
Latest News & Community Perspectives
Discussion
Women with transthyretin amyloid cardiomyopathy (ATTR-CM) showed different clinical characteristics than men with the condition in pooled data from two previous studies of patients treated with Vyndamax (tafamidis). Although women appeared more symptomatic…
Discussion
Early-career researchers studying transthyretin amyloidosis (ATTR), a group of conditions that includes hereditary ATTR with polyneuropathy (hATTR-PN) and ATTR cardiomyopathy (ATTR-CM), are being called to apply for one of two $100,000 research grants.
Discussion
The approved therapy Attruby (acoramidis) may not only slow the progression of transthyretin amyloid cardiomyopathy (ATTR-CM), but it may also help reverse heart damage, according to newly analyzed imaging data from a clinical…
Discussion
In people with transthyretin amyloid cardiomyopathy (ATTR-CM), treatment with the approved therapy Amvuttra (vutrisiran) may help reduce the risk of death and serious heart problems, with similar trends seen in patients who were and…
Discussion
A family history of nerve disease, carpal tunnel syndrome in both hands, and balance problems are the “clinical ‘red flags'” most strongly linked to a positive genetic test for mutations associated with hereditary transthyretin amyloidosis…
Discussion
The first participant has been dosed in a clinical trial evaluating the long-term effects of Attruby (acoramidis), an approved treatment for transthyretin amyloid cardiomyopathy (ATTR-CM), on heart function and structure in adults with…
Discussion
Biopsies taken during surgery for carpal tunnel syndrome, a condition that affects a wrist nerve, may help with early detection of transthyretin cardiac amyloidosis (ATTR-CM), a review study found. But the researchers cautioned…
Discussion
Although mutations that cause hereditary transthyretin amyloidosis with polyneuropathy (hATTR-PN) most frequently lead to nerve damage, they can also cause heart damage and other symptoms, a study highlights. The findings “emphasize the need for…
Discussion
Enrollment is open in a post-marketing clinical trial designed to investigate whether long-term treatment with Attruby (acoramidis) can reverse heart disease-related changes in people with transthyretin amyloid cardiomyopathy (ATTR-CM). The Phase 4 study,…
Discussion
A specific genetic variant may have contributed to signs of severe liver problems observed in a few patients given nexiguran ziclumeran (nex-z), an investigational gene-editing therapy for hereditary transthyretin amyloidosis with polyneuropathy (hATTR-PN) and the…